Board of Directors
Alan B. Colowick M.D., M.P.H., Chair
PARTNER, SOFINNOVA VENTURES
Dr. Colowick has served on our Board of Directors since February 2017. He has served as our Chair since April 2019 and served as our Executive Chair from February 2017 to April 2019. Since 2017, Dr. Colowick has served as a private equity partner at Sofinnova Venture Partners. From 2010 to 2017, Dr. Colowick held positions Celgene Corporation, including Executive Vice President. From 2008 to 2010, Dr. Colowick was the Chief Executive Officer at Gloucester Pharmaceuticals, Inc. until its acquisition by Celgene in 2010. From 2006 to 2008, Dr. Colowick was President, Oncology for Geron Corporation and from 2005 to 2006 was Chief Medical Office of Threshold Pharmaceuticals. From 1999 to 2005, Dr. Colowick held positions at Amgen Inc. Dr. Colowick previously served on the board of Achaogen, Inc. from March 2015 to July 2017 and on the board of Dimension Therapeutics, Inc. from August 2015 to November 2017. Dr. Colowick currently serves on the boards of InCarda Therapeutics, Inc., VelosBio, Inc., XyloCor Therapeutics, and Human Longevity, Inc. Dr. Colowick completed specialty training in Hematology-Oncology at the Dana Farber Cancer Institute/Brigham and Women’s Hospital. Dr. Colowick received a B.S. in Molecular Biology from the University of Colorado, an M.D. from Stanford University and an M.P.H from Harvard University. We believe Dr. Colowick is qualified to serve as a member of our Board of Directors due to his educational background in sciences, as well as financial understanding of the biotechnology industry gained from his operational and investing experience.
President and Chief Executive Officer, Principia Biopharma
Mr. Babler has served as our Chief Executive Officer since April 2011 and as our President and Chief Executive Officer since April 2019. From December 2007 to April 2011, Mr. Babler served as President and Chief Executive Officer of Talima Therapeutics, Inc., a pharmaceutical company. From 1998 to 2007, Mr. Babler held several positions at Genentech, Inc., a biopharmaceutical company, most notably as Vice President, Immunology Sales and Marketing. While at Genentech he also helped to build and lead the Commercial Development organization and led the Cardiovascular Marketing organization. From 1991 to 1998, Mr. Babler was employed at Eli Lilly and Company, a pharmaceutical company, in positions focused on sales, sales management, global marketing and business development. Mr. Babler presently serves on the Emerging Companies Section and Health Section Governing Boards of the Biotechnology Innovation Organization, or BIO, and was a board member of ZS Pharma, Inc., a biotechnology company, until its sale to AstraZeneca Inc., a pharmaceutical company. Mr. Babler holds a Swiss Federal Diploma in pharmacy from the Federal Institute of Technology in Zurich and completed the Executive Development Program at the Kellogg Graduate School of Management at Northwestern University. We believe that Mr. Babler is qualified to serve as a member of our Board of Directors based on the perspective and experience he brings as our President and Chief Executive Officer.
Dan Becker, M.D., Ph.D.
Principal, Access Biotechnology
Dr. Becker has served on our Board of Directors since 2017. Dr. Becker joined Access Industries in 2019 as a Principal in the Biotechnology group. From 2015 to 2019, Dr. Becker was a Principal at New Leaf Venture Partners. From 2009 to 2015, Dr. Becker was a Principal at the Boston Consulting Group where he was a core member of their Health Care practice and led projects across the health care sector with an emphasis on biopharma R&D. From 2006 to 2009, Dr. Becker trained clinically in internal medicine and nephrology at Brigham and Women’s Hospital and Massachusetts General Hospital, and was a Research Fellow at Harvard Medical School. He obtained both his M.D. and Ph.D. (Cellular and Molecular Biology) degrees from the University of Michigan, and received his B.S. in Physiology from the University of Illinois at Urbana-Champaign. We believe Dr. Becker is qualified to serve as a member of our Board of Directors due to his educational background in sciences, as well as financial understanding of the biotechnology industry gained from his venture capital experience.
Simeon George, M.D., M.B.A.
Partner, SR One
Dr. George has served on our Board of Directors since February 2011. Dr. George joined S.R. One, Limited in September 2007 as an Associate and later became Partner, and since February 2019 has served as Chief Executive Officer. From 2006 to 2007, Dr. George was a consultant at Bain & Company, and in 2004 he was an investment banker at Goldman Sachs and Merrill Lynch. Dr. George’s current directorships include BirdRock Bio, Inc., CRISPR Therapeutics, eFFECTOR Therapeutics, Inc., Progyny, Inc. and Turning Point Therapeutics, Inc. Dr. George received his B.A. in neuroscience from the Johns Hopkins University, where he graduated Phi Beta Kappa. He received his M.D. from the University of Pennsylvania School of Medicine and his M.B.A. (Mayer Scholar) from the Wharton School of the University of Pennsylvania. We believe Dr. George is qualified to serve as a member of our Board of Directors due to his educational background in sciences, as well as financial understanding of the biotechnology industry gained from his investing experience.
Shao-Lee Lin, M.D., Ph.D.
Executive Vice President, head of Research and Development and Chief Scientific Officer. Horizon Pharma
Dr. Lin has served on our Board of Directors since April 2019. Dr. Lin has served as Executive Vice President, Head of Research and Development and Chief Scientific Officer of Horizon Pharma plc, a biopharmaceutical company, since January 2018. Dr. Lin is an immunologist, rheumatologist and allergist with more than 20 years of academic and clinical research experience. Prior to Horizon, Dr. Lin was a corporate officer and Vice President, Therapeutic Areas, Development Excellence and International Development at AbbVie Inc., a pharmaceutical company, from March 2015 to December 2017. In that role, she led immunology, virology, neuroscience and general medicine, across on-market and pipeline compounds as well as international development across all therapeutic areas. Prior to AbbVie, Dr. Lin was Vice President, Inflammation and Respiratory Development at Gilead Sciences, Inc., a biopharmaceutical company, from July 2012 to February 2015. She also held leadership positions in immunology and other therapeutic areas while at Amgen, Inc., a biotechnology company. Dr. Lin received her medical degree and doctorate at the Johns Hopkins University School of Medicine and completed fellowships and post-doctoral work in rheumatology, allergy and immunology at the University of California San Diego and The Scripps Clinic and Research Institute. She received a Bachelor of Science in biochemistry and chemical engineering from Rice University. Dr. Lin has previously been on the faculty of Rockefeller University as a Clinical Scholar and also served as adjunct faculty at Cornell, University of California Los Angeles, Stanford and Northwestern medical schools. We believe that Dr. Lin is qualified to serve as a member of our Board of Directors based on her more than 20 years of academic and clinical research experience across multiple therapeutic areas.
Co-Founder and former Chief business and financial officer of Medivation
Mr. Machado co-founded Medivation, a biopharmaceutical company, in 2003 and served as its Chief Financial Officer from its inception in September 2003 until his retirement in April 2014, and as its Chief Business Officer from December 2009 until his retirement in April 2014. Mr. Machado served as a member of Medivation’s board of directors from April 2014 until the company was acquired by Pfizer in September 2016. His earlier experience includes senior finance, legal and business development roles at ProDuct Health, Inc. and Chiron Corporation. He currently serves as a member of the board of directors for several biotechnology companies, including Adverum Biotechnologies, Inc., Chimerix, Inc., and Turning Point Therapeutics, Inc., and previously served on the board of directors of Endocyte prior to its acquisition by Novartis. Earlier in his career, Mr. Machado worked for Morrison & Foerster LLP, an international law firm, and for the Massachusetts Supreme Judicial Court. Mr. Machado received a J.D. from Harvard Law School and a B.A. and B.S. in German and Economics, respectively, from Santa Clara University. We believe Mr. Machado is qualified to serve as a member of our Board of Directors due to his operational and financial understanding of the biotechnology industry gained from his extensive experience as both an executive and board member.
FORMER CHIEF commercial OFFICER OF Kite Pharma
Ms. Tomasello brings more than 30 years of experience in the pharmaceutical and biotech industries, Ms. Tomasello has substantial commercial and strategic experience. From 2015 to 2018, Ms. Tomasello was chief commercial officer at leading immuno-oncology cell therapy company Kite Pharma, which was acquired by Gilead Sciences. Prior to this, she served as chief commercial officer and oversaw the launch of Imbruvica at Pharmacyclics, Inc., which was subsequently acquired by AbbVie, Inc. Ms. Tomasello previously was president of the Americas, Hematology and Oncology at Celgene Corporation where she managed over $4 billion in product revenues and was instrumental in various global expansion and acquisition strategies. She has also held senior positions at Genentech, Pfizer Laboratories, Miles Pharmaceuticals and Procter & Gamble. She received an MBA from Murray State University and a B.S. in Marketing from the University of Cincinnati. We believe Ms. Tomasello is qualified to serve as a member of our Board of Directors due to her commercial and operational understanding of the biotechnology industry gained from her extensive experience as both an executive and board member.
In Memoriam: Lewis J. Shuster
Chief Executive Officer, Shuster Capital
Mr. Shuster founded Shuster Capital in 2002, as a strategic and operating advisor to life science companies. He had over 30 years of life science company experience. Mr. Shuster held executive management roles at several privately held and publicly traded life science organizations including: CEO of Kemia, President of the Genomics division of Invitrogen, EVP Corporate Development and CFO of Pharmacopeia, and EVP Operations and Finance at Human Genome Sciences. Throughout his career, Mr. Shuster served as director of over a dozen life sciences companies, including chairing audit committees of public companies. In addition to Principia Biopharma, Mr. Shuster’s recent board memberships included Active Motif, Cleave Biosciences, TissueNetix and Turning Point Therapeutics. Mr. Shuster received his B.A. in economics from Swarthmore College and his M.B.A. from Stanford University Graduate School of Business.